Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Hetero Labs/Sihuan Pharmaceutical

Drug Profile

Research programme: small molecule therapeutics - Hetero Labs/Sihuan Pharmaceutical

Alternative Names: Coronovirus (2019-nCoV) therapeutics

Latest Information Update: 02 Mar 2020

At a glance

  • Originator Hetero Biopharma; Sihuan Pharmaceutical Holdings Group
  • Class Anti-infectives; Antivirals; Cardiovascular therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections; Vascular disorders

Most Recent Events

  • 21 Feb 2020 Hetero labs and Sihuan Pharmaceuticals agree to co-promote and co-develop coronavirus therapeutics in China and India for Coronavirus infection
  • 12 Feb 2020 Early research in COVID-2019-infections in China (Unspecified)
  • 12 Feb 2020 Early research in COVID-2019-infections in India (Unspecified)

Development Overview

Introduction

Small molecule therapeutics are being developed by Hetero Labs and Sihuan Pharmaceutical for cardiovascular, cerebrovascular, neurological and infective indications including coronavirus strain (2019-nCoV, SARS-CoV-2). Early research is underway in China and India.

Company Agreements

In February 2020, Sihuan Pharmaceutical and Hetero Labs entered into a framework co-operation agreement. According to the terms of the agreement Sihuan Pharmaceutical will introduce Hetero Biopharma's anti-virals and anti-infection products. The cooperation includes product registration, research and development, technology transfer, raw materials supply and local manufacturing and commercialization of drugs in the fields of cardiovascular, cerebrovascular, neurology and anti-infective agents that include coronavirus (2019-nCoV) [1]

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Anti-infectives, Antivirals, Cardiovascular therapies, Small molecules
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    C (Cardiovascular System)

    S01A-D (Antivirals)

  • EPhMRA code

    C (Cardiovascular System)

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research China, India unspecified / unspecified Hetero Biopharma, Sihuan Pharmaceutical Holdings Group 12 Feb 2020
Vascular disorders cardiovascular and cerebrovascular diorders - Research China, India unspecified / unspecified Hetero Biopharma, Sihuan Pharmaceutical Holdings Group 12 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Hetero Biopharma Originator India
Sihuan Pharmaceutical Holdings Group Originator Hong-Kong
Sihuan Pharmaceutical Holdings Group Owner Hong-Kong
Hetero Biopharma Owner India

Development History

Event Date Update Type Comment
21 Feb 2020 Licensing Status Hetero labs and Sihuan Pharmaceuticals agree to co-promote and co-develop coronavirus therapeutics in China and India for Coronavirus infection [1] Updated 02 Mar 2020
12 Feb 2020 Phase Change Early research in COVID-2019-infections in China (Unspecified) [1] Updated 02 Mar 2020
12 Feb 2020 Phase Change Early research in COVID-2019-infections in India (Unspecified) [1] Updated 02 Mar 2020
12 Feb 2020 Phase Change Early research in Vascular disorders in China (Unspecified) [1] Updated 02 Mar 2020
12 Feb 2020 Phase Change Early research in Vascular disorders in India (Unspecified) [1] Updated 02 Mar 2020

References

  1. Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area.

    Media Release
Back to top